Posted on by admin

Inflammatory Myositis Market and Epidemiology 2032: Treatment Market, Therapies, Companies, FDA Approvals, Epidemiology and Forecast by DelveInsight | CSL Behring, Argenx, Priovant Therapeutics/Roivan

Inflammatory Myositis Market and Epidemiology 2032: Treatment Market, Therapies, Companies, FDA Approvals, Epidemiology and Forecast by DelveInsight | CSL Behring, Argenx, Priovant Therapeutics/Roivan
The Inflammatory Myositis Market size was valued approximately USD 575 million in 2022 and the report offers an in-depth understanding of the Inflammatory Myositis, historical and forecasted epidemiology as well as the Inflammatory Myositis market trends in the 7MM.

DelveInsight’s “Inflammatory Myositis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Inflammatory Myositis, historical and forecasted epidemiology as well as the Inflammatory Myositis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Inflammatory Myositis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Inflammatory Myositis Market Forecast

 

Some of the key facts of the Inflammatory Myositis Market Report: 

  • The Inflammatory Myositis market size was valued approximately USD 575 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)

  • In 2022, there were 184,204 confirmed cases of inflammatory myositis in the 7MM; by 2032, cases are predicted to rise at a 2.4% annual growth rate

  • Among the 7MM, the US had the most number of diagnosed prevalent cases of inflammatory myositis in 2022 (90,064), followed by the UK (68,079), EU4, Japan (26,060 cases), and other countries

  • In EU4 and the UK, there were 68,079 documented instances of inflammatory myositis in 2022. With 21,734 affected persons, Germany had the largest number of diagnosed prevalent cases, followed by Italy (14,776) and the UK (13,590). These cases are anticipated to rise in 2022 during the study period

  • Brepocitinib by Priovant Therapeutics/Roivant, Efgartigimod by Argenx, Hizentra developed by CSLBehring, and other potential Inflammatory Myositis therapies are anticipated to be launched within the projected period. These novel treatments show promise in the management of inflammatory myositis, and their introduction is anticipated to change the range of available treatments in the anticipated time frame.

  • Key Inflammatory Myositis Companies: CSL Behring, Argenx, Priovant Therapeutics/Roivant, Alexion Pharmaceuticals, Pfizer, Horizon Therapeutics, Eli Lilly and Company, Janssen Research & Development, Pfizer, Immunoforge Co. Ltd., Schering-Plough, GlaxoSmithKline, Roche Pharma AG, and others

  • Key Inflammatory Myositis Therapies: Hizentra, Efgartigimod, Brepocitinib, Ultomiris, PF-06823859, Daxdilimab, Baricitinib, Nipocalimab, PF-06823859, Froniglutide, Infliximab, Lovaza, Rituximab, and others

  • The Inflammatory Myositis epidemiology based on gender analyzed that females are more susceptible to suffer from Inflammatory myositis when compared to the male population, in the 7MM

  • The Inflammatory Myositis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Inflammatory Myositis pipeline products will significantly revolutionize the Inflammatory Myositis market dynamics.

 

Inflammatory Myositis Overview

Inflammatory myositis is a group of rare autoimmune disorders characterized by inflammation and weakness of the muscles. These conditions involve inflammation of the muscles (myositis), leading to muscle weakness, pain, and fatigue. There are several types of inflammatory myositis, including polymyositis, dermatomyositis, and inclusion body myositis, each with its own specific features and patterns of muscle involvement.

 

Get a Free sample for the Inflammatory Myositis Market Report:

https://www.delveinsight.com/report-store/inflammatory-myositis-im-market

 

Inflammatory Myositis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Inflammatory Myositis Epidemiology Segmentation:

The Inflammatory Myositis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Inflammatory Myositis

  • Prevalent Cases of Inflammatory Myositis by severity

  • Gender-specific Prevalence of Inflammatory Myositis

  • Diagnosed Cases of Episodic and Chronic Inflammatory Myositis

 

Download the report to understand which factors are driving Inflammatory Myositis epidemiology trends @ Inflammatory Myositis Epidemiology Forecast

 

Inflammatory Myositis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Inflammatory Myositis market or expected to get launched during the study period. The analysis covers Inflammatory Myositis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Inflammatory Myositis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Inflammatory Myositis Therapies and Key Companies

  • Hizentra: CSL Behring

  • Efgartigimod: Argenx

  • Brepocitinib: Priovant Therapeutics/Roivant

  • Ultomiris: Alexion Pharmaceuticals

  • PF-06823859: Pfizer

  • Daxdilimab: Horizon Therapeutics

  • Baricitinib: Eli Lilly and Company

  • Nipocalimab: Janssen Research & Development

  • PF-06823859: Pfizer

  • Froniglutide: Immunoforge Co. Ltd.

  • Infliximab: Schering-Plough

  • Lovaza: GlaxoSmithKline

  • Rituximab: Roche Pharma AG

 

Discover more about therapies set to grab major Inflammatory Myositis market share @ Inflammatory Myositis Treatment Market

 

Inflammatory Myositis Market Strengths

  • The therapeutic landscape is prolific in determining the efficacy, safety, and tolerability of novel drugs in patients with IM and its various types.

 

Inflammatory Myositis Market Opportunities

  • The rising data on overall Inflammatory Myositis prevalence and its subtypes is expected to add significantly to the patient pool.

 

Scope of the Inflammatory Myositis Market Report

  • Study Period: 2019–2032

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Inflammatory Myositis Companies: CSL Behring, Argenx, Priovant Therapeutics/Roivant, Alexion Pharmaceuticals, Pfizer, Horizon Therapeutics, Eli Lilly and Company, Janssen Research & Development, Pfizer, Immunoforge Co. Ltd., Schering-Plough, GlaxoSmithKline, Roche Pharma AG, and others

  • Key Inflammatory Myositis Therapies: Hizentra, Efgartigimod, Brepocitinib, Ultomiris, PF-06823859, Daxdilimab, Baricitinib, Nipocalimab, PF-06823859, Froniglutide, Infliximab, Lovaza, Rituximab, and others

  • Inflammatory Myositis Therapeutic Assessment: Inflammatory Myositis current marketed and Inflammatory Myositis emerging therapies

  • Inflammatory Myositis Market Dynamics: Inflammatory Myositis market drivers and Inflammatory Myositis market barriers 

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Inflammatory Myositis Unmet Needs, KOL’s views, Analyst’s views, Inflammatory Myositis Market Access and Reimbursement 

 

To know more about Inflammatory Myositis companies working in the treatment market, visit @ Inflammatory Myositis Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Inflammatory Myositis Market Report Introduction

2. Executive Summary for Inflammatory Myositis

3. SWOT analysis of Inflammatory Myositis

4. Inflammatory Myositis Patient Share (%) Overview at a Glance

5. Inflammatory Myositis Market Overview at a Glance

6. Inflammatory Myositis Disease Background and Overview

7. Inflammatory Myositis Epidemiology and Patient Population

8. Country-Specific Patient Population of Inflammatory Myositis 

9. Inflammatory Myositis Current Treatment and Medical Practices

10. Inflammatory Myositis Unmet Needs

11. Inflammatory Myositis Emerging Therapies

12. Inflammatory Myositis Market Outlook

13. Country-Wise Inflammatory Myositis Market Analysis (2019–2032)

14. Inflammatory Myositis Market Access and Reimbursement of Therapies

15. Inflammatory Myositis Market Drivers

16. Inflammatory Myositis Market Barriers

17.  Inflammatory Myositis Appendix

18. Inflammatory Myositis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/